Anti-excititoxic sustained release intraocular implants and related methods
First Claim
Patent Images
1. A biodegradable intraocular implant comprising:
- an anti-excitotoxic agent and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the antiexcitotoxic agent from the implant for at least about one week after the implant is placed in an eye.
2 Assignments
0 Petitions
Accused Products
Abstract
Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.
135 Citations
33 Claims
-
1. A biodegradable intraocular implant comprising:
an anti-excitotoxic agent and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the antiexcitotoxic agent from the implant for at least about one week after the implant is placed in an eye. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
18. A method of making a biodegradable intraocular implant, comprising the step of:
- extruding a mixture of an anti-excitotoxic agent and a biodegradable polymer component to form a biodegradable material that degrades at a rate effective to sustain release of an amount of the anti-excitotoxic agent from the implant for at least about one week after the implant is placed in an eye.
- View Dependent Claims (19, 20, 21, 22, 23)
- 24. A method of treating an ocular condition characterized by undesirable angiogenisis in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising an anti-excitotoxic agent and a biodegradable polymer matrix, wherein the implant degrades at a rate effective to sustain release of an amount of the anti-excitotoxic agent from the implant effective to reduce angiogenisis in the eye of the patient.
Specification